NEUROSCIENCE TECHNOLOGIES SLP

Their core work

Neuroscience Technologies is a Barcelona-based SME specializing in pain assessment technologies and neuroscience instrumentation. They provide tools and expertise for measuring, characterizing, and stratifying pain conditions — from neuropathic pain to chronic pain syndromes like endometriosis and bladder pain. Their contribution to EU projects centers on translating neuroscience knowledge into practical assessment methods, including biomarker identification and patient-reported outcome measures (PROMs). They sit at the intersection of medical device development and clinical pain research.

What they specialise in

How they've shifted over time

Neuroscience Technologies entered H2020 through fundamental pain research — DOLORisk (2015) studied risk factors for neuropathic pain, while PAIN-Net (2017) was a Marie Curie training network focused on basic pain science from molecules to humans. By 2018, their focus shifted toward clinical application with IMI-PainCare, which emphasizes practical tools: biomarkers, patient stratification, PROMs, and optimized management of acute and chronic pain conditions including endometriosis and bladder pain syndrome.

Moving from basic pain science toward translational tools — biomarkers, digital assessment, and patient stratification — positioning them for medtech and clinical trial support partnerships.

How they like to work

Neuroscience Technologies operates exclusively as a specialist participant, never leading consortia. With 59 unique partners across 16 countries from just 3 projects, they consistently join large, multi-national research consortia where their pain assessment expertise fills a specific technical niche. This pattern suggests they are a trusted specialist that consortium leaders recruit for their focused capabilities rather than a generalist seeking broad involvement.

Despite only three projects, they have built a substantial network of 59 partners across 16 countries, reflecting the large consortium sizes typical of health research. Their network spans major European pain research groups and includes both academic and industry partners through the IMI (Innovative Medicines Initiative) framework.

What sets them apart

Neuroscience Technologies occupies a rare niche as a private SME focused entirely on pain neuroscience instrumentation and assessment — most pain research organizations are universities or hospitals. Their participation in IMI-PainCare, a public-private partnership with pharmaceutical industry involvement, signals credibility with both academic researchers and pharma companies. For consortium builders, they offer a commercial partner that can bridge the gap between lab-based pain research and real-world clinical measurement.

Highlights from their portfolio

• IMI-PainCare
  An Innovative Medicines Initiative project bringing together academia and pharma to improve acute and chronic pain care — their most application-oriented and clinically relevant project.
• DOLORisk
  Their largest funded project (€466,588) and first H2020 entry, focused on understanding why some people develop neuropathic pain — a foundational question in the field.
• PAIN-Net
  A Marie Curie training network covering pain science from molecular to human level, indicating the company's involvement in training the next generation of pain researchers.